Evidence-Based Guide

Smoking Cessation

A physician's evidence-based guide to nicotine addiction, first-line medications, combination therapy, behavioral support, and what actually works in 2026.

What is the best treatment for smoking cessation in 2026?

For most adults who smoke, a 2022 JAMA review recommends combining medication with behavioral support, with varenicline or combination nicotine replacement therapy (patch plus lozenge or gum) as the preferred first choices. In the head-to-head EAGLES trial (8,144 participants), 6-month quit rates were 21.8% with varenicline, 16.2% with bupropion, 15.7% with the nicotine patch, and 9.4% with placebo, as reported in that review. A 2023 Cochrane review found high-certainty evidence that combination NRT works better than a single form (RR 1.27). The FDA removed varenicline’s boxed warning for neuropsychiatric events in December 2016; its current label still says to stop it and contact a clinician right away if mood or behavior changes. In the USPSTF 2021 evidence review, combined medication and behavioral support raised quit rates compared with minimal support or placebo (pooled RR 1.83). Cytisinicline remains investigational in the U.S.: the FDA issued a Complete Response Letter in June 2026 citing manufacturing and labeling issues, and the company reports no efficacy or safety deficiencies were identified. A licensed clinician, accessible via telehealth or in-person care, can review your history, screen for contraindications, and prescribe appropriate therapy.
Medically reviewed by Parth Bhavsar, MD. Updated July 18, 2026.

Key Takeaways

  • Cigarette smoking causes more U.S. deaths each year than any other preventable cause, and quitting before age 40 reduces the excess risk of death from continued smoking by about 90%.[2][18]
  • Three types of FDA-approved first-line medication work: varenicline, bupropion SR, and nicotine replacement therapy (NRT). In the head-to-head EAGLES trial, varenicline was more effective than bupropion, the nicotine patch, and placebo.[3]
  • Combination NRT (patch plus a fast-acting form) is more effective than any single NRT form (high-certainty Cochrane evidence, RR 1.27).[5]
  • Varenicline's boxed warning for neuropsychiatric events was removed by the FDA in December 2016.[4] In EAGLES, which included a cohort of people with psychiatric disorders, neither varenicline nor bupropion significantly increased neuropsychiatric adverse events compared with nicotine patch or placebo.[3]
  • Medication plus behavioral support beats minimal support (USPSTF pooled RR 1.83).[1] Quitlines, text programs, and counseling by phone or video are evidence-based, and quitline services are free to callers.[11][12][14]
  • Cytisinicline, an investigational partial agonist that was well tolerated in two U.S. Phase 3 trials, received an FDA Complete Response Letter in June 2026 citing manufacturing (cGMP) inspection observations and unfinished labeling; the company reports the FDA identified no efficacy or safety deficiencies. Achieve Life Sciences plans to resubmit the NDA in Q4 2026, with potential approval in the first half of 2027.[8][9][28]
  • Most quit attempts do not succeed on the first try: people who try to quit make an average of about 6 attempts before long-term success. Relapse is part of the process, not a failure state.[2]
Editorial medical illustration representing Smoking Cessation
Smoking cessation: an evidence-based overview from the TeleDirectMD medical team.

Tobacco smoking is a chronic disorder maintained by both physical nicotine dependence and learned behaviors.[2] This guide is a physician's evidence-based look at nicotine addiction, the FDA-approved medications that work, combination therapy, behavioral support, and what the evidence actually says about quitting for good in 2026. Material claims are cited to sources that were retrieved and checked.

Why nicotine is addictive

Nicotine acts on α4β2 nicotinic acetylcholine receptors in the brain. According to FDA labeling for varenicline, activating these receptors stimulates the mesolimbic dopamine system, which is believed to be the brain mechanism behind the reinforcement and reward people experience when they smoke.[21] Learned habits then tie smoking to everyday routines.[2]

When you stop, nicotine withdrawal follows. Common symptoms include:[30]

  • Craving a cigarette
  • Feeling restless or jumpy
  • Feeling irritable or grouchy
  • Trouble thinking clearly or concentrating
  • Feeling hungrier
  • Trouble sleeping
  • Feeling sad, anxious, or depressed

Withdrawal symptoms are strongest in the first few days or weeks, then get weaker and happen less often; the worst symptoms only last a few days to a couple of weeks.[30] Triggers such as morning coffee, alcohol, stress at work, or specific places can still prompt urges, which is why a quit plan includes avoiding triggers, at least temporarily, after you quit.[30] Quitting is not simply a matter of willpower. Quit smoking medications can help reduce withdrawal symptoms and make quitting easier.[30]

The health case for quitting

Cigarette smoking and secondhand smoke exposure cause more than 480,000 deaths each year in the United States. Smoking causes cancer, heart disease and stroke, lung diseases such as chronic obstructive pulmonary disease (COPD), type 2 diabetes, and harmful reproductive health effects, among other diseases.[19]

The benefits of quitting begin within minutes and continue for decades:[20]

  • Within minutes: heart rate drops
  • Within 24 hours: the nicotine level in the blood drops to zero
  • Within several days: the carbon monoxide level in the blood drops to that of someone who does not smoke
  • 1 to 12 months: coughing and shortness of breath decrease
  • 1 to 2 years: the risk of heart attack drops sharply
  • 3 to 6 years: the added risk of coronary heart disease drops by half
  • 10 to 15 years: the added risk of lung cancer drops by half

Approximately 34 million people in the U.S. smoke cigarettes.[2] In a large U.S. national survey cohort, adults who quit at ages 25 to 34, 35 to 44, or 45 to 54 gained about 10, 9, and 6 years of life, respectively, compared with those who kept smoking, and quitting before age 40 reduced the risk of death associated with continued smoking by about 90%.[18] Quitting has health benefits at any age, no matter how long or how much you have smoked.[20]

Years of life gained by age at quit Compared with continuing to smoke. Quitting before 40 cut the excess risk of death by about 90%. 0 2 4 6 8 10 12 Years of life gained ~10 yrs 25–34 ~9 yrs 35–44 ~6 yrs 45–54 Age at smoking cessation Source: Jha et al., NEJM 2013
Years of life gained by age at quitting, compared with continuing to smoke, in a U.S. National Health Interview Survey cohort. Quitting before age 40 reduced the excess risk of death from continued smoking by about 90%, and quitting has health benefits at any age.[18][20]

What's Changed in 2024 to 2026

Smoking cessation science is not standing still. Several developments change how a clinician (and a patient) should think about a modern quit plan.

Varenicline is available as a generic. Generic varenicline tartrate tablets are marketed with FDA labeling that carries the dosing and safety information covered below.[21] Prices vary by pharmacy, insurance, and discount program, so this guide does not list cash prices.

The boxed warning is gone, but monitoring still matters. The FDA removed varenicline's neuropsychiatric boxed warning in December 2016.[4] Current labeling describes a large randomized trial in which serious neuropsychiatric events were reported in 0.1% of varenicline-treated and 0.4% of placebo-treated patients without a psychiatric history, and in 0.6% of each group among patients with a psychiatric history. The label still tells patients to stop varenicline and contact a clinician immediately if agitation, depressed mood, or unusual changes in behavior or thinking occur, or if suicidal thoughts or behavior develop.[21]

Combination NRT is a strong over-the-counter option. High-certainty Cochrane evidence (16 trials, 12,169 participants) shows that a patch plus a fast-acting form (gum or lozenge) leads to higher long-term quit rates than any single NRT form (RR 1.27). The same review found high-certainty evidence that 4 mg nicotine gum works better than 2 mg gum.[5]

Cytisinicline NDA delayed, Complete Response Letter (June 22, 2026). The FDA issued a Complete Response Letter (CRL) to Achieve Life Sciences in June 2026, citing outstanding manufacturing-related observations from a current Good Manufacturing Practice (cGMP) inspection and final product labeling that was not completed by the FDA's action date. The company reports that the FDA identified no deficiencies regarding the clinical efficacy or safety of cytisinicline.[9] Achieve has named U.S.-based Adare Pharma Solutions as its new primary commercial manufacturer and plans to resubmit the NDA in the fourth quarter of 2026, with potential FDA approval in the first half of 2027.[9] In two U.S. Phase 3 trials with behavioral support, 12 weeks of cytisinicline raised end-of-treatment abstinence (weeks 9 to 12) compared with placebo, with odds ratios of 6.3 in ORCA-2 and 4.4 in ORCA-3. Continuous abstinence from weeks 9 to 24 was 21.1% versus 4.8% in ORCA-2 and 20.5% versus 4.2% in ORCA-3, and neither trial reported drug-related serious adverse events.[28][8]

E-cigarette evidence has continued to accumulate. The NEJM Hajek trial (2019) showed e-cigarettes outperformed NRT for 1-year abstinence when both were paired with behavioral support (18.0% vs 9.9%).[6] The USPSTF found the evidence on e-cigarettes for cessation insufficient (an "I" statement) and recommends directing patients to cessation treatments with proven effectiveness and established safety; no e-cigarette has been FDA-approved as a cessation aid.[16] E-cigarettes are not first-line.

Telehealth prescribing. Varenicline and bupropion are not controlled substances.[21][22] A clinician licensed where you are located during the visit can assess you by video and prescribe them when appropriate.

Decision Framework: OTC, Prescription, or Combination

ScenarioRecommended approachRationale
First serious quit attempt, no psychiatric or seizure historyVarenicline 12 weeks + behavioral supportA preferred initial option in a 2022 JAMA review; highest 6-month quit rate in EAGLES (21.8% vs 9.4% placebo)[2][3]
Prefer OTC, no doctor's visitCombination NRT: patch + lozenge or gumHigh-certainty evidence of superiority over single NRT (RR 1.27)[5]; a preferred initial option in the JAMA review[2]
History of seizures or eating disorderVarenicline or NRT (avoid bupropion)Bupropion is contraindicated in seizure disorder and in current or prior bulimia or anorexia nervosa[22]
Prior failed attempt on single medicationVarenicline + NRT patchLow-certainty evidence that the combination improves long-term abstinence vs varenicline alone (RR 1.33); more adverse events, mainly skin reactions[10]
Not ready for a hard quit date"Reduce to quit" with NRT, or the gradual varenicline scheduleNRT-assisted reduction doubled 6-month sustained abstinence vs placebo (RR 2.06)[7]; varenicline labeling includes a 24-week gradual approach[21]
Depression, anxiety, or other psychiatric illnessVarenicline or bupropion; NRT also an optionEAGLES found no significant increase in neuropsychiatric adverse events with varenicline or bupropion vs patch or placebo; in smokers with major depression, varenicline had the largest effect[3][15]; FDA removed the varenicline boxed warning in 2016[4]
PregnancyBehavioral support first-line; pharmacotherapy individualized with a clinicianUSPSTF: behavioral interventions (grade A); evidence on pharmacotherapy in pregnancy is insufficient (I statement)[16]
Cardiovascular disease, including a recent heart attackMedication is still an option; choose it with a clinicianIn EAGLES and its extension, serious cardiovascular events were rare and did not differ by treatment[29]; varenicline labeling reports more nonfatal MI and stroke than placebo in a stable-CVD trial, though events were infrequent[21]; OTC NRT labels say to ask a doctor first after a recent heart attack[23][24]
Adolescents (<18 years)Care guided by a pediatric clinician; this guide covers adultsUSPSTF found insufficient evidence on primary care cessation interventions for children and adolescents (I statement)[17]
Shared decision-making is the framework

The best quit plan is the one a patient will actually follow for the full course. FDA labeling sets the course lengths: 12 weeks for varenicline, 7 to 12 weeks for bupropion, and about 10 to 12 weeks for over-the-counter NRT.[21][22][23][24]

First-Line Medications

The FDA-approved first-line pharmacotherapies for smoking cessation are varenicline, bupropion sustained-release, and nicotine replacement therapy in five forms (patch, gum, lozenge, inhaler, and nasal spray).[16] Behavioral counseling and medication each work alone, but they are most effective when combined.[2] USPSTF pooled risk ratios versus minimal support or placebo: varenicline 2.24, bupropion 1.64, NRT 1.55, combined pharmacotherapy plus behavioral support 1.83.[1]

6-month continuous abstinence, EAGLES trial Randomized head-to-head trial, n=8,144. All arms received brief counseling at each visit. 0% 5% 10% 15% 20% 25% Varenicline 21.8% Bupropion SR 16.2% Nicotine patch 15.7% Placebo 9.4% 6-month continuous abstinence rate Source: Rigotti et al., JAMA 2022, reporting EAGLES (Anthenelli et al., Lancet 2016)
Six-month quit rates from the EAGLES trial (n=8,144), as reported in a 2022 JAMA review. All three active medications outperformed placebo; varenicline had the largest effect. Every arm also received brief cessation counseling at each visit.[2][3]

Varenicline (generic; formerly Chantix)

How it works: a partial nicotinic agonist that binds the α4β2 nicotinic acetylcholine receptor. It stimulates the receptor at a much lower level than nicotine while blocking nicotine from activating it, so smoking during treatment is less rewarding.[21]

Efficacy: in EAGLES, 6-month quit rates were 21.8% with varenicline versus 9.4% with placebo,[2] and varenicline was more effective than placebo, nicotine patch, and bupropion.[3] USPSTF pooled RR 2.24.[1]

Standard dosing (12 weeks): set a quit date and start 1 week before it, or start first and quit between days 8 and 35 of treatment. Days 1–3: 0.5 mg once daily. Days 4–7: 0.5 mg twice daily. Day 8 to end of treatment: 1 mg twice daily. Take it after eating with a full glass of water. For people who have quit at 12 weeks, the label recommends an additional 12 weeks to improve long-term abstinence. People with severe kidney disease need a lower dose.[21]

Common side effects: nausea (up to 30%), abnormal or vivid dreams, constipation, flatulence, and vomiting. For intolerable nausea, a dose reduction should be considered.[21]

Safety notes: the FDA removed the boxed warning for serious neuropsychiatric events in December 2016.[4] The label still warns about neuropsychiatric events, seizures, increased effects of alcohol, accidental injury (use caution driving or operating machinery), and sleepwalking, and it tells patients to stop the medicine and contact a clinician immediately if unusual mood or behavior changes occur.[21] Nicotine withdrawal itself can also bring sad, anxious, or depressed feelings.[30]

Cost: prices vary widely by pharmacy, insurance, and discount program, so ask your pharmacy or plan for current pricing.

Bupropion sustained-release (Zyban, Wellbutrin SR)

How it works: the exact way bupropion helps people stop smoking is not known; it is presumed to involve noradrenergic and/or dopaminergic mechanisms. It contains the same active ingredient as some antidepressants.[22]

Efficacy: in EAGLES, the 6-month quit rate was 16.2%,[2] and bupropion and the nicotine patch had similar effects versus placebo (odds ratios 2.07 and 2.15).[3] USPSTF pooled RR 1.64.[1]

Standard dosing (7–12 weeks): start while you are still smoking and set a target quit date within the first 2 weeks of treatment. Days 1–3: 150 mg once daily. Then 150 mg twice daily, at least 8 hours apart. Insomnia may be minimized by avoiding bedtime doses. With moderate to severe liver impairment, the dose should not exceed 150 mg every other day.[22]

Common side effects: insomnia, rhinitis, dry mouth, dizziness, nervous disturbance, anxiety, nausea, constipation, and joint pain. Bupropion carries a boxed warning about suicidal thoughts and behaviors because it contains the same active ingredient as antidepressants.[22]

Contraindications:

  • Seizure disorder (bupropion's seizure risk is dose-related)
  • Current or prior bulimia or anorexia nervosa
  • Abrupt discontinuation of alcohol, benzodiazepines, barbiturates, or antiepileptic drugs
  • MAO inhibitors for psychiatric disorders, now or within 14 days; starting bupropion in someone taking linezolid or intravenous methylene blue
  • Known allergy to bupropion or other ingredients of the product[22]

Depression: bupropion is the same active ingredient used to treat depression, but among smokers with major depression in EAGLES, varenicline showed the largest effect with a similar risk of neuropsychiatric adverse events.[15]

Nicotine replacement therapy (NRT)

How it works: NRT replaces some of the nicotine from cigarettes to reduce cravings and withdrawal symptoms and ease the transition to complete abstinence.[5]

Efficacy: USPSTF pooled RR 1.55.[1] In EAGLES, the nicotine patch produced a 15.7% 6-month quit rate.[2] Combination NRT, patch plus a fast-acting form, is superior to any single form (Cochrane RR 1.27).[5]

FormRouteAvailabilityTypical dosing per FDA labeling
PatchTransdermalOTCMore than 10 cigarettes a day: 21 mg/day weeks 1–6, 14 mg weeks 7–8, 7 mg weeks 9–10[23]
GumBuccalOTC4 mg if first cigarette within 30 minutes of waking, otherwise 2 mg; 1 piece every 1–2 hours in weeks 1–6 (at least 9 a day), tapering through week 12; max 24 a day[24]
LozengeBuccalOTCSame 4 mg or 2 mg rule; 1 every 1–2 hours in weeks 1–6 (at least 9 a day), tapering through week 12; max 5 in 6 hours and 20 a day[25]
InhalerOral inhalationPrescription6–16 cartridges a day for up to 12 weeks, then gradual reduction[26]
Nasal sprayIntranasalPrescription1 dose = 2 sprays (one per nostril); start 1–2 doses an hour, at least 8 a day, no more than 5 an hour or 40 a day[27]

Medication comparison

MedicationTypical courseAvailabilityEfficacy vs placebo
Varenicline (generic)12 weeks[21]PrescriptionRR 2.24[1]
Bupropion SR7–12 weeks[22]PrescriptionRR 1.64[1]
Combination NRT (patch + lozenge/gum)About 10–12 weeks (per product labels)[23][24][25]OTCRR 1.55 (single-form baseline); combination RR 1.27 over single[1][5]
Nicotine patch (single-form NRT)10 weeks[23]OTCRR 1.55[1]
Nicotine gum or lozenge (single-form)12 weeks[24][25]OTCRR 1.55[1]
Cytisinicline6 or 12 weeks (in trials)[8][28]Investigational, FDA CRL Jun 22, 2026; resubmission planned Q4 2026[9]OR 4.4–6.3 for end-of-treatment abstinence in Phase 3 (12-week arms)[8][28]

Prices vary by pharmacy, insurance, and discount program, so this guide does not list cash prices. Some state quitlines offer free cessation medications.[11]

Building combination NRT:

  • Patch: follow the label step-down (for more than 10 cigarettes a day: 21 mg in weeks 1–6, 14 mg in weeks 7–8, 7 mg in weeks 9–10).[23]
  • Fast-acting form: add gum or lozenge for cravings. Patch plus a fast-acting form is the combination the Cochrane review found more effective than a single form.[5]
  • How much: agree on the number of pieces with your clinician or pharmacist, and stay under each label's daily maximum (24 pieces of gum or 20 lozenges).[24][25]

Common side effects and correct use:

  • Patch: skin irritation; stop and ask a doctor if redness lasts more than four days, the skin swells, or a rash appears. If you have vivid dreams or other sleep disturbances, you may remove the patch at bedtime.[23]
  • Gum: correct technique: chew slowly until it tingles, then "park" the gum between your cheek and gum; when the tingle fades, chew again, for about 30 minutes. Do not chew one piece after another. Stop and ask a doctor if mouth, teeth, or jaw problems occur.[24]
  • Lozenge: let it dissolve slowly and minimize swallowing; do not chew or swallow it. Stop and ask a doctor if mouth problems, persistent indigestion, or a severe sore throat occur.[25]

"Reduce to quit" is evidence-based. For smokers who are not ready to quit abruptly, using NRT to cut down doubled the rate of 6-month sustained abstinence versus placebo (RR 2.06; meta-analysis of trials enrolling 2,767 smokers), though most of the evidence came from trials with regular behavioral support.[7] Varenicline labeling also describes a gradual approach: reduce smoking by 50% within the first four weeks, by another 50% in the next four weeks, and continue treatment for a total of 24 weeks.[21] This is a valid entry point for ambivalent quitters.

Combination Therapy: When One Isn't Enough

Combining drugs with different mechanisms of action, such as varenicline and NRT, has increased quit rates in some studies compared with a single product.[2]

Combination NRT (patch + short-acting)

The default OTC combination. A long-acting patch provides steady baseline nicotine; a fast-acting form (gum, lozenge) is used for breakthrough cravings. High-certainty Cochrane evidence: RR 1.27 versus single-form NRT.[5] Both components are sold over the counter in the United States.[23][24]

Varenicline + NRT

A 2025 meta-analysis (7 trials, 2,631 participants) found low-certainty evidence that varenicline plus NRT may improve long-term quit rates compared with varenicline alone (RR 1.33, 95% CI 1.04–1.69); the result was no longer statistically significant when the trial at high risk of bias was excluded. Adverse events, especially skin reactions with the patch, were more common with the combination, and serious adverse events were infrequent and generally unrelated to treatment.[10] It is an option to discuss with a clinician after a failed attempt on varenicline alone.

Bupropion + NRT

In a network meta-analysis of smokers with medical or psychiatric illnesses, bupropion plus NRT ranked best overall and beat either drug alone in people with mental illness, but overall confidence in the evidence was low.[13] In practice, this combination is most useful when a patient is already on bupropion for depression and adding NRT to address cessation specifically.

Plan for the full course

Labeling sets 12 weeks for varenicline (plus another 12 weeks for people who have quit), 7 to 12 weeks for bupropion, and about 10 to 12 weeks for OTC NRT.[21][22][23][24] Discussing this expectation upfront is one of the most useful things a clinician can do.

Behavioral Support: The Multiplier

Medication addresses the pharmacology of nicotine addiction; behavioral support addresses the habit, the triggers, and the identity change of becoming a non-smoker. In a meta-analysis of 19,488 people who smoked, medication plus behavioral counseling produced a 6-month quit rate of 15.2% versus 8.6% with brief advice or usual care.[2] USPSTF pooled RR for combined pharmacotherapy and behavioral interventions: 1.83 versus minimal support or placebo.[1]

Behavioral support options are evidence-based and often free:

Quitlines (1-800-QUIT-NOW). Calling 1-800-QUIT-NOW automatically transfers you to your state's quitline; services are confidential and free to callers, and some state quitlines offer free cessation medications.[11] A 2019 Cochrane review of 104 trials found that, among smokers who called quitlines, multiple sessions of proactive telephone counseling raised quit rates compared with self-help materials or brief counseling in a single call (RR 1.38, moderate-certainty evidence).[12]

Text-message programs. The National Cancer Institute's SmokefreeTXT (text QUIT to 47848) sends daily text messages to adults in the U.S. who are ready to quit.[31] In the UK txt2stop RCT (n=5,800, Lancet 2011), biochemically verified continuous abstinence at 6 months was 10.7% in the text-message arm vs 4.9% in control (RR 2.20, 95% CI 1.80–2.68).[14]

Smartphone apps. The National Cancer Institute's quitSTART app offers tips, information, and games.[11]

In-person, phone, or telehealth counseling. Brief or intensive behavioral support can be delivered effectively in person or by telephone, text messages, or the internet.[2]

Clinician-delivered brief counseling. Clinicians use the 5 A's (Ask, Advise, Assess, Assist, Arrange follow-up).[16] Even minimal advice from a clinician (a single session under 20 minutes) was associated with higher quit rates than no advice,[16] and the USPSTF evidence review found a pooled RR of 1.76 for advice from clinicians.[1] Every clinical encounter is a legitimate cessation opportunity.

The behavioral support multiplier Relative risk of quitting vs each study's control condition. Higher = larger effect. 0× 0.5× 1× 1.5× 2× 2.5× RR = 1 (no effect) Text-message program (txt2stop) Lancet 2011 RR 2.20 Combined pharma + behavioral USPSTF 2021 RR 1.83 Advice from clinicians USPSTF 2021 RR 1.76 Proactive phone counseling (quitline callers) Cochrane 2019 RR 1.38 Relative risk of quitting vs control (higher is better)
The behavioral support multiplier. Medications work; medications plus structured behavioral support work better. Text-message programs (RR 2.20),[14] combined medication and behavioral support (RR 1.83) and clinician advice (RR 1.76),[1] and proactive telephone counseling for quitline callers (RR 1.38)[12] all deliver meaningful gains at low or no cost.

E-Cigarettes: A Nuanced Evidence Base

E-cigarettes are not FDA-approved as a smoking cessation aid; the FDA classifies them as tobacco products. In its 2021 recommendation, the U.S. Preventive Services Task Force found the evidence insufficient to assess the benefits and harms of e-cigarettes for cessation (an "I" statement).[16] However, the research base has grown, and a nuanced discussion is warranted.

The strongest single trial: the Hajek NEJM 2019 RCT enrolled 886 adults attending UK National Health Service stop-smoking services and compared an e-cigarette starter pack with NRT products of the participant's choice. At 1 year, biochemically validated sustained abstinence was 18.0% in the e-cigarette arm versus 9.9% in the NRT arm (RR 1.83, 95% CI 1.30–2.58). Both arms received weekly behavioral support for at least 4 weeks. Among people abstinent at 1 year, 80% of the e-cigarette group were still using e-cigarettes, compared with 9% of the NRT group still using NRT.[6]

Why USPSTF is still cautious:

  • Data on potential long-term harms of e-cigarette use are lacking
  • Product variability: the e-cigarettes tested varied across studies, making comparisons difficult
  • Dual use: toxicant levels in people who use both e-cigarettes and cigarettes may be higher
  • High rates of e-cigarette use among children and adolescents in the U.S.[16]

The reasonable clinical stance in 2026: e-cigarettes are not first-line. The USPSTF recommends directing people who use tobacco to cessation treatments with proven effectiveness and established safety.[16] If you already use e-cigarettes, talk with a clinician about a plan to stop smoking completely and then stop vaping, and avoid long-term dual use.

Smoking Cessation in Special Populations

Patients with mental illness

All three first-line medications work in people with psychiatric illness. The EAGLES trial enrolled 4,116 people in its psychiatric cohort and found:[3]

  • Varenicline produced higher abstinence than placebo, nicotine patch, and bupropion, and the efficacy comparisons did not differ by cohort
  • Moderate and severe neuropsychiatric adverse events were more common in the psychiatric cohort (4.9% to 6.7% across groups) than in the non-psychiatric cohort, but the differences between the medications and placebo were not statistically significant[3]

A secondary analysis of EAGLES participants with major depressive disorder found varenicline plus counseling had the largest effect, with a risk of neuropsychiatric adverse events that did not differ by medication.[15] Bupropion labeling notes that in the psychiatric cohort the composite neuropsychiatric event rate was higher with bupropion than with placebo.[22] Whichever medication is chosen, labeling advises stopping it and contacting a clinician if unusual mood or behavior changes occur.[21][22]

Pregnancy

The USPSTF recommends behavioral interventions for pregnant persons who smoke (grade A); the evidence on pharmacotherapy in pregnancy is insufficient (an "I" statement).[16] In pooled trials, validated quit rates with NRT in pregnancy were not significantly different from placebo.[1] Smoking during pregnancy increases the risk of miscarriage, congenital anomalies, stillbirth, preterm birth, low birth weight, and sudden infant death syndrome,[16] so medication decisions are individualized after discussing risks and benefits with an obstetric clinician.

Cardiovascular disease

In EAGLES and its extension trial (8,058 treated smokers), cardiovascular events were rare (under 0.5% for major events) and did not differ significantly by treatment, which supports that varenicline, bupropion, and the nicotine patch do not increase serious cardiovascular events in the general population of smokers.[29] The evidence for people with established heart disease is less direct: varenicline labeling reports that in a trial of patients with stable cardiovascular disease, events were infrequent overall, but nonfatal heart attack and stroke occurred more often with varenicline than with placebo.[21] In a network meta-analysis, varenicline and bupropion improved quit rates versus placebo in smokers with cardiovascular disease.[13] OTC NRT labels say to ask a doctor before use if you have heart disease, a recent heart attack, or an irregular heartbeat.[23][24] Choose a medication with your clinician.

Adolescents

This guide is written for adults. For children and adolescents who already smoke, the USPSTF found insufficient evidence to assess primary care cessation interventions (an "I" statement), citing a lack of adequately powered behavioral counseling studies and a lack of medication studies.[17] Young people who want to quit should work with a pediatric clinician.

Postoperative and hospitalized patients

A hospital stay is a natural moment to quit. In a 2024 Cochrane review, counseling that began in the hospital and continued for more than a month after discharge raised quit rates (RR 1.36, high-certainty evidence), and starting NRT in the hospital also helped (RR 1.33, high-certainty evidence).[32]

Post-Cessation Weight Gain

Weight gain after quitting is common and can discourage some people from making a quit attempt.[34] The reality:

  • Mean weight gain at 12 months: about 4 to 5 kg (roughly 9 to 11 pounds), with most of it in the first three months. Variation is large: about 16% of quitters lose weight and 13% gain more than 10 kg.[33]
  • Feeling hungrier is a common nicotine withdrawal symptom.[30]
  • Quitting still pays off for the heart. In the Framingham Offspring cohort, recent quitters without diabetes had a lower risk of cardiovascular disease than people who kept smoking (HR 0.47), and the weight gained after quitting did not change that association.[35]

Practical strategies:

  • Increase physical activity. In trials, exercise had little effect on weight by the end of treatment, but weight was lower at 12 months.[34]
  • Mindful eating. Watch for snacking-as-substitute-oral-behavior; keep sugar-free gum or vegetables handy.
  • NRT and bupropion limit weight gain during treatment. There was no clear evidence of a lasting effect at 12 months, and varenicline's effect on weight was very small.[34]

Preventing Relapse

Most quit attempts do not succeed on the first try. People who try to quit make an average of about 6 quit attempts before achieving long-term abstinence.[2] Among people who try to quit without treatment, most relapse occurs in the first 8 days.[36] Relapse is not a failure state, it is a normal part of the process.

Common relapse risks you can plan for:

  1. Stopping medication early. Complete the full course on the label even if you feel confident.[21][22]
  2. High-risk situations without a plan. Alcohol, social events with other smokers, morning coffee, workplace stress. Anticipate these and script your response.
  3. The "just one" belief. Plan ahead for how you will handle the urge to have a single cigarette, and get back on track quickly if you slip.
  4. Untreated depression or anxiety. Contact a clinician early if mood symptoms persist.
  5. Weight gain concerns. Address proactively (see above); do not let modest weight gain trigger a relapse.
  6. Isolation. Support from family, friends, quitline coaches, or peer groups can help.

If you relapse: retry. Varenicline labeling encourages another attempt once the factors that contributed to the failed attempt have been identified and addressed.[21] The medication that failed once may succeed on a second attempt, particularly if it was stopped early. Alternatively, switch to combination therapy.

What Doesn't Work

Cessation is a category where the evidence base is unusually strong, which also makes it clear which approaches lack support.

Hypnotherapy. A 2019 Cochrane review found insufficient evidence that hypnotherapy is more effective than other behavioral support or unassisted quitting; if there is a benefit, it is small at most.[37] It should not substitute for evidence-based treatment.

Acupuncture and related techniques. A Cochrane review found no consistent, bias-free evidence that acupuncture, acupressure, or laser therapy has a sustained benefit for six months or more, and electrostimulation is not effective.[38]

"Detox" supplements, herbal cessation pills, and "quit smoking" homeopathic products. These are not among the FDA-approved cessation medicines (NRT, bupropion SR, and varenicline).[16] Stick with treatments that have trial evidence.

Cigarette reduction alone (without pharmacotherapy or behavioral support). Simply cutting back is not the same as the NRT-assisted reduction tested in trials, most of which also included regular behavioral support (see the "reduce to quit" strategy above).[7]

Cold turkey without support. Willpower alone works for a small minority: only 3% to 5% of people who try to quit without treatment achieve prolonged abstinence for 6 to 12 months.[36] This is not a moral failing. Every serious quit attempt should include, at minimum, either medication or behavioral support, and ideally both, which work best together.[2]

On "gas station" nicotine products

OTC-style "quit smoking aids" sold at gas stations or convenience stores that are not FDA-approved NRT (patch, gum, lozenge from a known manufacturer) or a known prescription medication are not a substitute for evidence-based therapy. If a product cannot show FDA approval or a credible clinical trial, it does not belong in a quit plan.

Red Flags: When to Seek Immediate Medical Attention

During a quit attempt, contact a clinician promptly if you experience:

  • New or worsening depression, agitation, unusual changes in behavior or thinking, or thoughts of self-harm. Stop varenicline or bupropion and contact a clinician immediately.[21][22]
  • New seizure (particularly if on bupropion): stop bupropion, do not restart it, and seek emergency evaluation.[22]
  • Signs of an allergic reaction (rash, swelling, difficulty breathing) while using NRT or varenicline. Stop the product and seek care.[21][24]
  • Chest pain, arm pain, sudden shortness of breath, or an irregular heartbeat or palpitations. Seek prompt evaluation; NRT labels say to stop and ask a doctor if irregular heartbeat or palpitations occur.[23]
  • Symptoms of nicotine overdose while using NRT, such as nausea, vomiting, dizziness, diarrhea, weakness, and rapid heartbeat. Stop and ask a doctor.[24]
  • New or worsening cough with blood-streaked sputum, or a persistent cough that does not resolve. Long-term smokers should have any new or persistent respiratory symptoms evaluated.
  • Skin reaction under a nicotine patch: redness that lasts more than four days, swelling, or a rash. Stop using the patch and ask a doctor.[23]
  • Persistent or intolerable nausea on varenicline. Ask your clinician about a dose reduction.[21]

Frequently Asked Questions

Withdrawal symptoms are strongest in the first few days or weeks, and the worst usually last a few days to a couple of weeks.[30] Triggers such as coffee, alcohol, stress, or specific places can keep prompting urges after that, so plan for them. A standard varenicline course is 12 weeks, with another 12 weeks recommended for people who have quit, and bupropion runs 7 to 12 weeks.[21][22]

In the head-to-head EAGLES trial, varenicline produced the highest quit rate (21.8% at 6 months).[2][3] A 2022 JAMA review names varenicline or combination NRT (patch plus a fast-acting form, available over the counter) as the preferred first choices.[2][5] In EAGLES, bupropion and the nicotine patch had similar effects, both lower than varenicline.[3] The best medication is the one you will actually take for the full course.

For most people, yes, with monitoring. The EAGLES trial enrolled 4,116 people with psychiatric disorders and found no significant increase in neuropsychiatric adverse events with varenicline versus placebo or nicotine patch.[3] The FDA removed the boxed warning for varenicline in December 2016.[4] The label still advises stopping varenicline and contacting a clinician immediately if agitation, depressed mood, or unusual changes in behavior or thinking occur, or if suicidal thoughts or behavior develop.[21]

Both approaches can work. With varenicline, you can set a quit date and start 1 week before it, start and then quit between days 8 and 35, or use the label's gradual 24-week approach.[21] With bupropion, you start while still smoking and set a quit date within the first 2 weeks.[22] For people not ready to quit abruptly, "reduce to quit" using NRT doubled 6-month sustained abstinence versus placebo (RR 2.06).[7] Pick the approach that matches your readiness.

Prices vary widely by pharmacy, insurance plan, and discount program, so this guide does not list cash prices; ask your pharmacy or plan for current pricing. Varenicline is available as a generic, and nicotine patches, gum, and lozenges are sold over the counter.[21][23][24][25] Some state quitlines offer free cessation medications.[11]

Not first-line. In one UK trial, e-cigarettes beat NRT for 1-year abstinence (Hajek NEJM 2019, 18.0% vs 9.9%), with both groups getting behavioral support.[6] But data on long-term harms are lacking, no e-cigarette is FDA-approved for quitting, and the USPSTF found the evidence insufficient.[16] If you already use them, talk with a clinician about a plan to stop smoking completely and then stop vaping. Dual use, continuing combustible cigarettes alongside e-cigarettes, should be avoided; toxicant levels in dual users may be higher.[16]

Most people gain some weight: on average about 4 to 5 kg (roughly 9 to 11 pounds) by 12 months, with wide variation.[33] Quitting still lowers cardiovascular risk, and in a large community cohort the weight gained after quitting did not change that benefit.[35] Bupropion and NRT limit weight gain during treatment, but the long-term effect is unclear; varenicline's effect is very small.[34]

Varenicline: 12 weeks, with an additional 12 weeks recommended for people who have quit at 12 weeks.[21] Bupropion: 7 to 12 weeks, with ongoing treatment considered case by case.[22] OTC NRT: about 10 weeks for the patch and 12 weeks for gum or lozenge.[23][24][25] Do not stop medication early because you feel confident; finish the course and talk with your clinician before stopping.

Yes. Varenicline and bupropion are not controlled substances.[21][22] A clinician licensed where you are located during the visit can assess you by video and prescribe them when appropriate. Nicotine patches, gum, and lozenges are sold over the counter, and the nicotine inhaler and nasal spray are prescription products.[23][24][25][26][27]

You are the norm, not the exception: people who try to quit make an average of about 6 attempts before long-term success.[2] Retry with the same medication (particularly if the reason for failure was stopping too early), or switch strategies: single medication to combination therapy (varenicline plus NRT, or combination NRT), single behavioral support to medication plus quitline plus text program, or an abrupt quit to a "reduce to quit" approach.[7][10][21]

Not yet. As of July 2026, cytisinicline is investigational in the United States. In June 2026, the FDA issued a Complete Response Letter to Achieve Life Sciences citing manufacturing-related observations from a cGMP inspection and final product labeling that was not completed by the action date; the company reports that the FDA identified no deficiencies regarding the drug's clinical efficacy or safety.[9] Achieve has named Adare Pharma Solutions as its new primary commercial manufacturer and plans to resubmit the NDA in Q4 2026, with potential FDA approval in the first half of 2027.[9] Two U.S. Phase 3 placebo-controlled trials (ORCA-2 and ORCA-3) showed higher quit rates than placebo and good tolerability, with no drug-related serious adverse events.[28][8]

The 5A model is a brief, structured counseling approach used by clinicians to address tobacco use: Ask about tobacco use, Advise to quit through clear, personalized messages, Assess willingness to attempt a quit, Assist with medication and behavioral resources, and Arrange follow-up.[16] Even minimal advice from a clinician (a single session under 20 minutes) was associated with higher quit rates than no advice.[16] Every clinical encounter is a legitimate cessation opportunity.

References

  1. Patnode CD, Henderson JT, Coppola EL, et al. Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;325(3):280-298. PubMed
  2. Rigotti NA, Kruse GR, Livingstone-Banks J, Hartmann-Boyce J. Treatment of Tobacco Smoking: A Review. JAMA. 2022;327(6):566-577. PubMed
  3. Anthenelli RM, Benowitz NL, West R, et al. Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet. 2016;387(10037):2507-2520. PubMed
  4. Pfizer Inc. CHANTIX (varenicline) tablets, for oral use: prescribing information. Revised 12/2016 (Recent Major Changes: Boxed Warning removed 12/2016). Drugs@FDA. FDA label (PDF)
  5. Theodoulou A, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2023;6(6):CD013308. PubMed
  6. Hajek P, Phillips-Waller A, Przulj D, et al. A Randomized Trial of E-Cigarettes versus Nicotine-Replacement Therapy. N Engl J Med. 2019;380(7):629-637. PubMed
  7. Moore D, Aveyard P, Connock M, et al. Effectiveness and safety of nicotine replacement therapy assisted reduction to stop smoking: systematic review and meta-analysis. BMJ. 2009;338:b1024. PubMed
  8. Rigotti NA, Benowitz NL, Prochaska JJ, et al. Cytisinicline for Smoking Cessation: The ORCA Phase 3 Replication Randomized Clinical Trial. JAMA Intern Med. 2025;185(6):648-655. PubMed
  9. Achieve Life Sciences. Achieve Life Sciences Receives Complete Response Letter from FDA for Cytisinicline NDA. Company press release, June 22, 2026. Press release
  10. Zhou X, Huang Z, Song Q, et al. Efficacy of combined varenicline and nicotine replacement therapy compared with varenicline or nicotine replacement therapy alone for smoking cessation: A systematic review and meta-analysis. Addiction. 2025;121(3):499-509. Full text (PMC)
  11. Centers for Disease Control and Prevention. Quitlines and Other Cessation Support Resources. Last reviewed January 31, 2025. Accessed November 7, 2026. CDC page
  12. Matkin W, Ordóñez-Mena JM, Hartmann-Boyce J. Telephone counselling for smoking cessation. Cochrane Database Syst Rev. 2019;5(5):CD002850. PubMed
  13. Xing X, Shang X, Deng X, et al. Efficacy and safety of pharmacological intervention for smoking cessation in smokers with diseases: A systematic review and network meta-analysis. J Evid Based Med. 2023;16(4):520-533. PubMed
  14. Free C, Knight R, Robertson S, et al. Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. Lancet. 2011;378(9785):49-55. PubMed
  15. Cinciripini PM, Kypriotakis G, Green C, et al. The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial. Depress Anxiety. 2022;39(5):429-440. PubMed
  16. US Preventive Services Task Force. Tobacco Smoking Cessation in Adults, Including Pregnant Persons: Interventions. Final recommendation statement, January 19, 2021 (published in JAMA. 2021;325(3):265-279). Page notes an update in progress. Accessed November 7, 2026. USPSTF recommendation
  17. US Preventive Services Task Force. Primary Care Interventions for Prevention and Cessation of Tobacco Use in Children and Adolescents: US Preventive Services Task Force Recommendation Statement. JAMA. 2020;323(16):1590-1598. PubMed
  18. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. N Engl J Med. 2013;368(4):341-350. PubMed
  19. Centers for Disease Control and Prevention. Cigarette Smoking. Last reviewed September 17, 2024. Accessed November 7, 2026. CDC page
  20. Centers for Disease Control and Prevention. Benefits of Quitting Smoking. Last reviewed May 15, 2024. Accessed November 7, 2026. CDC page
  21. Rhodes Pharmaceuticals L.P. Varenicline tartrate tablet, film coated: prescribing information. Revised 9/2025. DailyMed. Accessed November 7, 2026. DailyMed label
  22. GlaxoSmithKline LLC. ZYBAN (bupropion hydrochloride) sustained-release tablets: prescribing information. Revised 3/2021. DailyMed. Accessed November 7, 2026. DailyMed label
  23. Haleon US Holdings LLC. NicoDerm CQ (nicotine patch, extended release): Drug Facts. Revised 7/2025. DailyMed. Accessed November 7, 2026. DailyMed label (PDF)
  24. Lil' Drug Store Products, Inc. Nicorette White Mint (nicotine polacrilex gum, chewing): Drug Facts. Revised 12/2024. DailyMed. Accessed November 7, 2026. DailyMed label
  25. Rite Aid Corporation. Nicotine polacrilex lozenge: Drug Facts. Revised 9/2026. DailyMed. Accessed November 7, 2026. DailyMed label
  26. Pfizer (repackaged by Physicians Total Care, Inc.). NICOTROL (nicotine inhalation system): prescribing information. Updated December 10, 2009. DailyMed. Accessed November 7, 2026. DailyMed label
  27. Pharmacia & Upjohn Company LLC. NICOTROL NS (nicotine nasal spray): prescribing information. Updated May 29, 2025. DailyMed. Accessed November 7, 2026. DailyMed label
  28. Rigotti NA, Benowitz NL, Prochaska J, et al. Cytisinicline for Smoking Cessation: A Randomized Clinical Trial. JAMA. 2023;330(2):152-160. PubMed
  29. Benowitz NL, Pipe A, West R, et al. Cardiovascular Safety of Varenicline, Bupropion, and Nicotine Patch in Smokers: A Randomized Clinical Trial. JAMA Intern Med. 2018;178(5):622-631. PubMed
  30. National Cancer Institute, Smokefree.gov. Managing Nicotine Withdrawal. Undated web page. Accessed November 7, 2026. Smokefree.gov page
  31. National Cancer Institute, Smokefree.gov. SmokefreeTXT Quit Smoking Text Program. Undated web page. Accessed November 7, 2026. Smokefree.gov page
  32. Streck JM, Rigotti NA, Livingstone-Banks J, et al. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2024;5(5):CD001837. PubMed
  33. Aubin HJ, Farley A, Lycett D, et al. Weight gain in smokers after quitting cigarettes: meta-analysis. BMJ. 2012;345:e4439. PubMed
  34. Hartmann-Boyce J, Theodoulou A, Farley A, et al. Interventions for preventing weight gain after smoking cessation. Cochrane Database Syst Rev. 2021;10(10):CD006219. PubMed
  35. Clair C, Rigotti NA, Porneala B, et al. Association of smoking cessation and weight change with cardiovascular disease among adults with and without diabetes. JAMA. 2013;309(10):1014-1021. PubMed
  36. Hughes JR, Keely J, Naud S. Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction. 2004;99(1):29-38. PubMed
  37. Barnes J, McRobbie H, Dong CY, et al. Hypnotherapy for smoking cessation. Cochrane Database Syst Rev. 2019;6(6):CD001008. PubMed
  38. White AR, Rampes H, Liu JP, et al. Acupuncture and related interventions for smoking cessation. Cochrane Database Syst Rev. 2014;(1):CD000009. PubMed

About the Author

Parth Bhavsar, MD

Dr. Bhavsar is a board-certified family medicine physician, founder of TeleDirectMD, and the physician editor of the TeleDirectMD Health Guides. He practices multi-state urgent care telemedicine with hospitalist experience.

Medically reviewed by Parth Bhavsar, MD. Last reviewed and fully rewritten July 18, 2026.